Shots:

• Tilt initiates the collaboration with Merck KGaA & Pfizer to evaluate TILT-123 with avelumab in patients with solid tumors refractory to routine modalities
• TILT-123 will evaluate for solid tumors in the US & Europe and preclinical results of the dual combination- TILT technology and anti-PDL1 agent demonstrated immune activation & efficacy
• Bavencio (avelumab) is an anti-PD-L1 antibody act by blocking the interaction of PD-L1 with PD-1 receptors- co-develop & co-commercialize by Merck KGaA & Pfizer under the agreement signed in Nov’14. TILT-123 is an oncolytic adenovirus- replicates only in cancer cells producing immunostimulatory cytokines locally at the tumor site

Click here to read full press release/ article

Ref: Business Wire | Image: Merck KGaA